Dr Doger de Spéville on Key Efficacy Findings From Part C of TACTI-002 in HNSCC

Bernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma.

Related Keywords

Spain , Madrid , Fundacion Jimenez Diaz , , Early Phase Clinical Trials Unit , Phase 2 Tacti 002 Trial , Ct03625323 , Eftilagimod Alpha , Pembrolizumab , Head And Neck Squamous Cell Carcinoma , Hnscc , Bernard Doger De Spéville , Asco 2023 ,